Truscreen Market Update

NZX Announcement

20 June 2019
TruScreen Market Update
Highlights
• SUS (Single Use Sensor) sales increasing
• Vietnam pilot cervical cancer screening programme secured
• China market update
Cervical cancer technology company TruScreen Ltd’s (NZX: TRU) (the Company) provides this market
update on its various commercial operations.
SUS sales increasing
FY2019 saw substantial year on year, and quarter on quarter, growth in Single Use Sensor (SUS) sales.
The TruScreen device utilises a disposable SUS for every patient. As installation and use of devices grow,
so too will the demand for SUS.
In Q1 FY2019, SUS sales surged to 21,290,
from 3,400 in the prior corresponding period
(pcp). China accounted for almost half of
quarterly sales, with 10,260 units.
In Q2 FY2019, SUS sales rose 62% to 22,860
(pcp: 14,260).
SUS sales in Q3 FY2019 more than doubled,
to 25,560 (pcp: 12,240). Sales in China
accounted for more than half of the overall
SUS sales for the quarter.

In Q4 FY2019, SUS sales continued to grow, at 38,700 - up by almost half (pcp: 16,200). China
continued to account for half of overall SUS sales.
TruScreen secures Vietnam pilot cervical cancer screening programme
TruScreen continues to secure opportunities in Asia, winning approval to conduct a pilot cervical cancer
screening programme in Vietnam. Cervical cancer is the seventh most frequent cancer among women in
the region.
Vietnam has over 4,000 cervical cancer diagnoses each year and 26 million women of screening age but
no national screening programme.
The Vietnam Ministry of Health's Professional Advisory Committee has reviewed TruScreen and
approved a pilot cervical cancer screening programme to be conducted at the Hanoi Obstetrics and
3,400
14,260
12,240
16,200
21,290
22,860
25,560
38,700
0
5,000
10,000
15,000
20,000
25,000
30,000
35,000
40,000
45,000
Q1Q2Q3Q4
FY2018FY2019

Gynaecology Hospital - Vietnam’s most prestigious government hospital. The Hanoi ObGyn Hospital
considers TruScreen a viable technology for cervical cancer screening in Vietnam.
The pilot programme will evaluate the TruScreen device prior to a national rollout to all provinces.
One thousand women will be screened as part of stage 1 of the programme and 5,000 in stage 2.
A TruScreen delegation, led by the Chairman of the Company’s Medical Advisory Committee, Prof.
Neville Hacker, visited Vietnam in early June 2019.
Prof. Hacker and the Company’s Clinical Affairs Manager, Dr. Carolina Velasquez, met with key medical
advisers to the Ministry of Health, including the Director of Hanoi Obstetrics and Gynaecology Hospital,
Prof. Anh, to discuss the national adoption of TruScreen.
China market update
COGA evaluation
TruScreen’s large-scale evaluation programme with China’s Obstetrics and Gynaecology Association
(COGA) is progressing well, with eight out of the 10 participating provinces already launching the
programme, and 52 hospitals already screening women.
The large-scale evaluation, which was announced in July 2018, will screen over 20,000 women in 100
top-tier public hospitals, across 10 provinces in China.
The evaluation is anticipated to continue throughout the 2020 financial year, and results are expected
to be released in FY2021.
Two Cancer Centre rollout
Sixteen of the planned 50 “Two Cancer Centres” are established, with TruScreen installed.
During FY2019, TruScreen was chosen as the primary screening solution for the high-tech, privately
owned and operated clinics, which provide a ‘one-stop’ screening diagnosis and treatment for breast
and cervical cancer. Most clinics are to be located in government hospitals.
As part of the rollout, TruScreen’s local distributor network are holding promotional meetings with key
decision-makers, highlighting the success of TruScreen in the 16 established centres.
CDC evaluation
The statistical department of the Women’s and Children’s Division of the Centre for Disease Control
(CDC) in China is currently analysing clinical data from the large-scale evaluation with the CDC that was
completed in late FY2019. TruScreen anticipates publication of results in mid-FY2020.
This evaluation included the screening of over 12,000 women throughout China. The evaluation aims to
have TruScreen included in the CDC’s screening guidelines for the 3,000 hospitals run by its Women’s
and Children’s Health Division. The evaluation also aims to have the CDC recommend TruScreen for
inclusion in the Central Government’s Ministry of Health screening guidelines for all 12,000 government
hospitals in China.
-ENDS-

For more information visit www.TruScreen.com or contact:

TruScreen
Martin Dillion
CEO
martindillon@truscreen.com

TruScreen
Guy Robertson
CFO
guyrobertson@truscreen.com
Investors
Investor Relations
Phone: +61 2 9237 2801
TruScreen@we-buchan.com

About TruScreen:
Watch our video on TruScreen: http://truscreen.com/truscreen-the-company/truscreen- ultra-video/
TruScreen is a Cervical Cancer Screening Device which offers
the latest technology in cervical screening, providing real-time,
accurate detection of pre-cancerous and cancerous cervical
cells to help improve the health and well-being of women
around the world. TruScreen’s real-time cervical cancer
technology utilises a digital wand which is placed on the surface
of the cervix to measure electrical and optical signals from the
surrounding tissues. A sophisticated proprietary algorithm
framework is utilised to detect pre-cancerous change, or cervical
intraepithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.
TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with
Pap tests including failed samples, poor patient follow up, patient discomfort and the need for
supporting laboratory infrastructures. As such, TruScreen target market is developing countries where
no large scale cervical cancer screening programs and infrastructure are in place, such as; China, Mexico,
Africa, Russia and India. TruScreen’s cervical cancer screening device is EC certified for use throughout
Europe and CFDA approved for sale in China. Truscreen gained recognition from Global NGO’s WHO and
Unitaid in a joint Cervical Cancer Technology Landscape released at the 72
nd
World Health Assembly.
For more information, visit our website at www.truscreen.com